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Detecting the Recurrence of Gastric Cancer after Curative 
Resection: Comparison of FDG PET/CT and Contrast-Enhanced 
Abdominal CT
The purpose of this study was to evaluate the value of fluorodeoxyglucose positron 
emission tomography/computed tomography (FDG PET/CT) for detecting the recurrence of 
gastric cancer. We performed a retrospective review of 139 consecutive patients who 
underwent PET/CT and contrast-enhanced abdominal CT (CECT) for surveillance of gastric 
cancer after curative resection. Recurrence of gastric cancer was validated by 
histopathologic examination for local recurrence or serial imaging study follow-up with at 
least 1 yr interval for recurrence of distant metastasis form. Twenty-eight patients (20.1%) 
were confirmed as recurrence. On the patient based analysis, there was no statistically 
significant difference in the sensitivity, specificity and accuracy of PET/CT (53.6%, 84.7%, 
and 78.4%, respectively) and those of CECT (64.3%, 86.5%, and 82.0%, respectively) for 
detecting tumor recurrence except in detection of peritoneal carcinomatosis. Among 36 
recurrent lesions, 8 lesions (22.2%) were detected only on PET/CT, and 10 lesions (27.8%) 
only on CECT. PET/CT had detected secondary malignancy in 8 patients. PET/CT is as 
accurate as CECT in detection of gastric cancer recurrence after curative resection, 
excepting detection of peritoneal carcinomatosis. Moreover, additional PET/CT on CECT 
could improve detection rate of tumor recurrence and provide other critical information 
such as unexpected secondary malignancy.
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INTRODUCTION
Gastric cancer is the second most common cause of cancer death 
worldwide (1). Within the Asian region, the incidence of gastric 
cancer is high, and it is the most common cancer in Korea (2).
  Complete surgical resection of gastric cancer is considered 
potentially curative, but its long-term survival is frequently re-
ported as poor. In fact, despite successful surgery, the five-year 
survival rate is approximately 35%; and even with adjuvant che-
motherapy in selected patients, the survival rate is 40% (3). After 
curative surgery, about 80% of the patients die within a short 
period of time from locoregional recurrence (87%) and/or dis-
tant metastasis (30%) (4).
  To detect the gastric cancer recurrence, various methods such 
as tumor markers, endoscopy or imaging studies have been used. 
Contrast-enhanced abdominal computed tomography (CECT) 
has been most popularly used imaging study in diagnosing re-
current gastric cancer. To date, however, only few reports have 
been published on CECT findings after gastrectomy (5, 6). They 
described that CECT lacks specificity particularly in diagnosing 
local recurrence because its diagnostic capability is based on only 
the morphologic changes of the involved organs, and distorted 
anatomic structures make image interpretation difficult (5).
  Positron emission tomography (PET) with 
18F-fluorodeoxy-
glucose (FDG) is a non-invasive technique for determination of 
metabolically active lesions, which has been widely used for re-
staging or follow-up after treatment in various cancers (7-9). 
However, unlike the other cancers, only limited number of re-
ports is available on the use of PET or integrated PET/CT in de-
tecting recurrent gastric cancer (1, 10-14).
  The purpose of this study was to evaluate the efficacy of PET/
CT for detecting gastric cancer recurrence after curative resec-
tion, and to compare the diagnostic accuracy of FDG PET/CT 
with that of CECT.
MATERIALS AND METHODS
Patients
Between August 2007 and July 2008, 139 consecutive patients 
(age, 61.5 ± 11.6 yr; 88 men and 51 women) were retrospectively Kim D-W, et al.  •  Recurrent Gastric Cancer on PET/CT
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enrolled for this investigation. The study inclusion criteria were 
as follows: 1) an interval of less than 3 yr between curative sur-
gical resection and study inclusion, 2) both integrated PET/CT 
and CECT were performed within 2 months for the surveillance 
of gastric cancer recurrence with or without suspicion of recur-
rence, and 3) for suspicious lesion of local or distant recurrence, 
histopathologic confirmation through endoscopic biopsy or se-
rial imaging study follow-up for at least 1 yr interval, were per-
formed.
  The initial treatment methods of these patients included total 
gastrectomy (n = 12), proximal gastrectomy (n = 6), radical sub-
total gastrectomy with Billroth anastomosis (n = 116), endoscop-
ic mucosal resection (n = 4) and wedge resection (n = 1). Their 
histopathologic types included adenocarcinoma (n = 117), sig-
net ring cell carcinoma (n = 19), mucinous adenocarcinoma (n = 
1) and others (n = 2). All patients underwent follow-up gastros-
copy, CECT and PET/CT scans after surgery at 3 to 6 months 
intervals. The follow-up period from initial surgery to the final 
confirmation of recurrence ranged from 3.6 to 46.2 months (18.5 
± 9.0 months). A mean interval between CECT and PET/CT scans 
was 11 days. The final confirmation for the presence or absence 
of recurrence was done histopathologically in 25 patients (en-
doscopic biopsy, n = 22; surgery, n = 2; percutaneous biopsy, n 
= 1) and radiologically in 114 patients. These final confirmations 
were considered as gold standards for patient or organ based 
analysis.
CECT and FDG PET/CT scanning
All follow-up CECT scans were performed with multi-detector 
row CT scanners (Somatom Volume Zoom, Siemens AG, Enlan-
gen, Germany), spanning from the liver dome to the pelvic floor. 
Each patient drank 200 mL of water just before undergoing CECT. 
Scanning was started 45 sec after the intravenous injection of 
100-120 mL of iopromide (Ultravist 300, Schering Korea, Seoul, 
Korea) at a rate of 3 mL/sec. A slice collimation of 1.2 mm and a 
table pitch of 1:1 were used. Images were reconstructed at 5 mm 
intervals.
  FDG was prepared using a cyclotron (RDS-111, CTI Cyclo-
tron Systems, Inc., Daejeon, Korea) and automated synthesis 
apparatus. The radiochemical and chemical purity of the prod-
uct was assayed by analytic high-performance liquid chroma-
tography and thin-layer chromatography and was consistently 
> 99% by both assays. The measured specific activity of the FDG 
was > 740 GBq/mM at the end of synthesis. Patients fasted for 
at least 8 hr and drank 300 mL of water just before undergoing 
FDG PET/CT. The PET/CT scan was started 55-60 min after the 
administration of 296-444 MBq FDG using an integrated PET/
CT system (Biograph Sensation 16, Siemens Medical Systems, 
Munich, Germany). The axes of both systems are mechanically 
aligned to coincide optimally. CT data were acquired first and 
the following parameters were used: tube rotation time 0.5 sec 
per revolution, 120 kV, 140 mAs, reconstructed slice thickness 5 
mm. No contrast medium was used for the CT examination. Af-
ter the CT data had been completely acquired, the table top with 
the patient automatically advanced into the PET sensitive field 
of view and acquisition of PET data was started in three-dimen-
sional mode with the patient in exactly the same position on the 
table. Scanning was performed in one bed position for 3 min. 
The attenuation correction was automatically completed using 
corresponding CT data.
Image analysis
All recurrent lesions were classified into 5 categories: 1) locore-
gional recurrence, the recurrence in remnant stomach or anas-
tomotic site, 2) regional lymph node (RegLN) recurrence, the 
recurrence in pancreatic, splenic and perigastric lymph nodes 
along the lesser and greater curvatures, 3) liver, the recurrence 
of hepatic metastasis form, 4) peritoneal carcinomatosis, and 5) 
distant recurrence, the recurrence in lymph node or organ ex-
cepting the liver. Multiple lesions within one category were con-
sidered as a one lesion.
  All CECT images were analyzed retrospectively by two expe-
rienced abdominal radiologists by means of consensus, who 
were aware that the patient had curative resection due to gastric 
cancer. The lesion at anastomotic site showing mucosal and/or 
wall thickening with contrast enhancement was considered as 
locoregional recurrence. Enlarged lymph node (short axis ≥ 10 
mm) or contrast enhancing mass was considered as regional, 
liver or distant recurrence according to the location of lesion. The 
nodules, loculated fluid collections, or irregular, beaded thicken-
ing and stranding of the mesentery or omentum on CECT scans, 
were considered as findings of peritoneal carcinomatosis.
  PET/CT images also were reviewed retrospectively by two ex-
perienced nuclear medicine physicians, who were aware that the 
patient had curative resection due to gastric cancer. The review-
ers reached a consensus in cases of discrepancy. FDG PET/CT 
scans were interpreted visually, and maximum standardized up-
take value (SUV) was recorded when abnormal non-physiologic 
metabolic activity was identified. Quantification of tumor met-
abolic activity was obtained using the SUV normalized to body 
weight. Focal hypermetabolic activity of anastomotic site or rem-
nant stomach was considered locoregional tumor recurrence. 
Focal hypermetabolic activity within the liver which was greater 
than adjacent normal liver tissue was considered abnormal. Mul-
tinodular or diffuse hypermetabolic activities along the intestine 
or mesentery were considered as findings of peritoneal carci-
nomatosis. Diffuse or segmental hypermetabolism with mild 
activity in the intestinal tract was interpreted as a normal physi-
ologic uptake. When abnormal hypermetabolic lesions suggest-
ing secondary malignancy were detected, further evaluations 
including radiologic and histopathologic examinations were rec-
ommended.Kim D-W, et al.  •  Recurrent Gastric Cancer on PET/CT
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Statistical analysis
Patient and organ based sensitivity, specificity and accuracy were 
calculated using crosstab tables. McNemar’s test was used to 
analyze the difference between PET/CT and CECT in diagnos-
tic performances. Where applicable, data are presented as mean 
± SD. Data were analyzed using descriptive statistics, and changes 
in continuous variables were analyzed using the independent-
samples T test. Tests with P value < 0.05 were considered signif-
icant.
Ethics statement
This study was approved by the institutional review board of the 
Wonkwang University Hospital (No. 7303-61) and informed con-
sent was not required for this retrospective study.
RESULTS
During follow-up periods, 28 patients (20.1%) were confirmed 
having recurrent disease. Thirty-six lesions were confirmed as 
recurrence (locoregional, n = 7; RegLN, n = 7; liver, n = 4; perito-
neal carcinomatosis, n = 11; distant, n = 7). 
Detection of recurrence using CECT and PET/CT
On the patient based analysis, there was no statistically signifi-
cant difference in the sensitivity, specificity and accuracy of 
PET/CT (53.6%, 84.7%, and 78.4%, respectively) and those of 
CECT (64.3%, 86.5%, and 82.0%, respectively) for detecting tu-
mor recurrence except in detection of peritoneal carcinomato-
sis. On the organ based analysis, PET/CT was more accurate to 
detect the liver and distant recurrence, but it was not statistical-
ly significant. CECT was more sensitive to detect peritoneal car-
cinomatosis, and it was statistically significant (P = 0.021). The 
diagnostic performances between two methods were not statis-
tically different except in detection of peritoneal carcinomato-
sis. The sensitivity, specificity and accuracy according to the re-
current organs are described in Table 1.
  Among 36 recurrence lesions, 8 lesions (22.2%) were detected 
only on PET/CT, and 10 lesions (27.8%) only on CECT (Table 2). 
Nine lesions (25%) were detected on both PET/CT and CECT, 
and both methods could not detect the remaining 9 lesions (25%). 
The mean SUV of gastric anastomotic site was significantly high-
er in patients with locoregional recurrence (3.4 ± 3.1) than those 
without locoregional recurrence (1.9 ± 0.7, P < 0.05).
Additional value of PET/CT
PET/CT had detected 15 lesions which were not related to the 
recurrence of gastric cancer. Radiologic, endoscopic and histo-
pathologic evaluations had revealed secondary malignancy in 8 
patients (colon cancer, n = 4; thyroid cancer, n = 3; prostatic can-
cer, n = 1) and other benign pathology in 7 patients (active pul-
monary tuberculosis, n = 4; chronic thyroiditis, n = 3).
  The diagnostic accuracy of PET/CT for detecting the recur-
rence was not compromised in the patients with histopatholog-
ic type of signet-ring cell carcinoma, compared to the patients 
of adenocarcinoma (Table 3).
Table 1. The diagnostic performance of FDG PET/CT and contrast-enhanced abdomi-
nal CT (CECT) according to the recurrence sites
Site FDG PET/CT CECT  P value
Patient-based (%)
   Sensitivity 
   Specificity 
   Accuracy 
 
53.6
84.7
78.4
 
64.3
86.5
82.0
 
1.0
Locoregional (%)
   Sensitivity 
   Specificity 
   Accuracy 
 
42.9
88.6
86.3
 
42.9
94.7
92.1
 
0.152
Regional lymph node (%)
   Sensitivity 
   Specificity 
   Accuracy 
 
28.4
99.2
95.7
  
28.6
98.5
95.0
 
1.0
Peritoneum (%)
   Sensitivity 
   Specificity 
   Accuracy 
 
18.2
100.0
93.5
 
63.6
97.7
95.0
 
0.021
Liver (%)
   Sensitivity 
   Specificity 
   Accuracy 
 
75.0
99.3
98.6
 
50.0
94.8
93.5
 
0.180
Distant (%)
   Sensitivity 
   Specificity 
   Accuracy 
 
100.0
98.5
98.6
 
71.4
95.5
94.2
 
0.754
FDG, 
18F-fluorodeoxyglucose; PET/CT, positron emission tomography/computed 
tomo  graphy. 
Table 2. Recurred lesions according to the findings on FDG PET/CT and contrast-en-
hanced abdominal CT (CECT)
CECT
 Positive (%)  Negative (%)
FDG PET/CT
   Positive 9 (25)    8 (22.2)
   Negative  10 (27.8) 9 (25)
FDG, 
18F-fluorodeoxyglucose; PET/CT, positron emission tomography/computed 
tomo  graphy. 
Table 3. The diagnostic performance of FDG PET/CT and contrast-enhanced abdomi-
nal CT (CECT) according to the histopathologic types of primary gastric cancer
Imaging modality
Adenocarcinoma  
(n = 117)
Signet-ring cell  
adenocarcinoma (n = 19)
FDG PET/CT (%)
   Sensitivity
   Specificity 
   Accuracy 
 
52.0
83.7
76.9
 
50.0
88.2
84.2
CECT (%)
   Sensitivity
   Specificity 
   Accuracy
 
68.0
87.0
82.9
 
50.0
82.4
78.9
FDG, 
18F-fluorodeoxyglucose; PET/CT, positron emission tomography/computed 
tomo  graphy. Kim D-W, et al.  •  Recurrent Gastric Cancer on PET/CT
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DISCUSSION
The present study showed that PET/CT was as sensitive and spe-
cific as CECT in the detection of gastric cancer recurrence except 
for peritoneal carcinomatosis. Considering that eight recurrent 
lesions (22.2%) were detected only on PET/CT and secondary 
malignancy was revealed in 8 patients, additional value of PET/
CT was also evident.
  The optimal method for assessing early recurrence in patients 
with gastric cancer is unknown (15). Conventional imaging (ul-
trasonography, CECT and magnetic resonance imaging) has 
represented the standard for staging and restaging of gastric can-
cer (16, 17). Conventional imaging is noninvasive and is the least 
costly of the available methods, although it has limited value in 
differentiating post-surgical changes from local tumor recur-
rence. Therefore, these techniques have limitations for accurate 
restaging (15, 18).
  There have been some reports about the role of FDG PET or 
integrated PET/CT in the evaluation of gastric cancer recurrence 
after curative resection. However, their results were inconsistent. 
Jadvar et al. (10) reported that FDG PET might be useful in the 
post-therapy evaluation of recurrent disease. Sim et al. (12) and 
Park et al. (13) also suggested that PET/CT might have a role for 
detecting recurrence in post-operative patients with gastric can-
cer. On the other hand, De Potter et al. (19) reported that FDG 
PET might not be suitable as a primary tool for follow up due to 
its moderate accuracy.
  The diagnostic performance of PET/CT might be compro-
mised for several reasons. First, due to physiological uptake in 
the bowel, a sufficient tumor-to-background ratio cannot be 
obtained, especially in small lesions located in the lumen of  
the alimentary tract, which can be evaluated only by endosco-
py. Second, PET/CT has relatively lower sensitivity in detecting 
peritoneal carcinomatosis because of the small size of the le-
sions (19, 20). Peritoneal carcinomatosis which is flat and small-
er than 1 cm, is very difficult to detect when using the currently 
available PET hardware with a spatial resolution of 6-8 mm (19). 
Moreover, the number of patients with peritoneal carcinomato-
sis was relatively large. In this study population, it was 11/28 
(39.3%). Third, it has been reported that signet ring cell carcino-
ma and mucinous adenocarcinoma showed significantly low 
FDG uptake (21). As a result, lower sensitivity and accuracy in 
patients with signet cell carcinoma and mucinous adenocarci-
noma, was reported from the studies evaluating primary lesion 
of gastric malignancy. However, our results were not consistent 
with these findings, although the number of patients was not 
large (n = 20).
  On the other hand, many metabolically active conditions can 
cause FDG uptake, thus decreasing the specificity of PET in de-
tecting malignant lesions. These false positive conditions in the 
abdomen encompass various kinds of physiologic uptakes in 
the abdominal organs as well as benign pathologic conditions. 
Physiologic uptakes are commonly found in the gastrointesti-
nal and urinary tracts. Physiologic uptake in the gastrointestinal 
tract is due to smooth muscle contraction and metabolically ac-
tive mucosa, whereas that in the urinary tract may be explained 
by the fact that FDG is not reabsorbed by the renal tubules after 
glomerular filtration (22).
  In spite of these disadvantages of PET/CT, results of this study 
could encourage the routine use of additional PET/CT on CECT 
in the evaluation of gastric cancer recurrence after curative re-
section. In this study, among 36 recurrence lesions, 8 lesions 
(22.2%) were detected only on PET/CT, and 10 lesions (27.8%) 
only on CECT. Only 9 lesions (25%) were detected on both PET/
CT and CECT. Moreover, PET/CT had revealed unexpected sec-
ondary malignancy in 8 patients (colon cancer, n = 4; thyroid 
cancer, n = 3; prostatic cancer, n = 1) and other benign patholo-
gy in 7 patients. These results might be enough to justify clinical 
role of PET/CT in the detection of gastric cancer recurrence.
  This study had enrolled patients whose interval between cu-
rative surgical resection and study inclusion was less than 3 yr. 
This criterion was based on the report of Wu et al. (23). They re-
ported that most (73.5%) recurrences of gastric cancer took place 
within the first 18 months after surgery, with continued but mark-
edly decreased attribution in the third year. Nearly 90% of the 
recurrences occurred within 3 yr, and only 7.3% occurred be-
tween the third and fifth years. These data suggest that an intense 
surveillance of recurrence might be needed in the initial 3 yr af-
ter surgery.
  Our study had several limitations. The first was the retrospec-
tive nature of our study. Because of this nature, we were unable 
to standardize the interval and methods of follow-up imaging 
studies and gastroscopy. This nature also could cause selection 
bias, because the patients who had not undergone CECT or PET/ 
CT were excluded. Second, recurrent lesions were not always 
evaluated histopathologically. Therefore, there was the possibil-
ity of including cases in which false-positive lesions were con-
sidered as true-positive lesions by imaging follow-up. Finally, 
our image analysis method was conducted by radiologists and 
nuclear medicine physicians independently. If additional im-
age analysis using a consensus of both radiologist and nuclear 
medicine physician was conducted, the clinical role of PET/CT 
could be revealed more clearly.
  In conclusion, despite several limitations, our results revealed 
that PET/CT is as accurate as CECT in the detection of gastric 
cancer recurrence after curative resection, except for detecting 
peritoneal carcinomatosis. Moreover, additional use of PET/CT 
on CECT could improve detection rate of tumor recurrence and 
provide other critical information such as unexpected second-
ary malignancy. Kim D-W, et al.  •  Recurrent Gastric Cancer on PET/CT
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Detecting the Recurrence of Gastric Cancer after Curative Resection: Comparison of 
FDG PET/CT and Contrast-Enhanced Abdominal CT
Dae-Weung Kim, Soon-Ah Park and Chang Guhn Kim
In a retrospective review of 139 patients underwent curative resection of gastric cancer, we compared fluorodeoxyglucose positron 
emission tomography/computed tomography (FDG PET/CT) with contrast-enhanced abdominal CT (CECT) for detecting the 
recurrence of gastric cancer. There was no significant difference in the diagnostic accuracy of PET/CT and that of CECT for 
detecting tumor recurrence except in detection of peritoneal carcinomatosis (CECT>FDG PET/CT). Among 36 recurrent lesions of 
28 patients, 8 lesions and 10 lesions were detected only on PET/CT and CECT, respectively. PET/CT had detected secondary 
malignancy in 8 patients. PET/CT is as accurate as CECT in the detection of gastric cancer recurrence. Combined application of PET/
CT and CECT could improve detection rate and provide other critical information such as unexpected secondary malignancy.